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ABSTRACT: Recent network and system biology analyses
suggest that most complex diseases are regulated by robust
and highly interconnected pathways that could be better
modulated by small molecules binding to multiple biological
targets. These pieces of evidence recently led to devote efforts
on identifying single chemical entities that bind to two
different disease-relevant targets. Here, we first predicted in
silico and later confirmed in vitro that UPF 1069, a known
bioactive poly(ADP-ribose) polymerase-1/2 (PARP1/2)
molecule, and hydroxyfasudil, a known bioactive Rho-
associated protein kinase-1/2 (ROCK1/2) molecule, have
low-micromolar cross-affinity for ROCK1/2 and PARP1/2, respectively. These molecules can now be regarded as chemical
seeds from which pharmacological tools could be generated to study the impact of dual inhibition of PARPs and ROCKs in
preclinical models of a variety of complex diseases where both targets are involved.
■ INTRODUCTION
The modulation of the activity of a specific protein by a small
molecule is one of the cornerstones of modern target-based
drug discovery.1 However, it is increasingly recognized that
small-molecule drugs often bind to multiple protein targets, a
phenomenon termed as polypharmacology that influences both
drug efficacy and safety.2,3 Albeit far less commonly studied,
the polypharmacology of drug metabolites and pharmaco-
logical tools is increasingly appreciated and can have profound
implications in fundamental studies of biological systems using
small molecules as pharmacological tools.4,5 Moreover,
evidence from network and system biology analyses suggests
that most diseases are regulated by robust and highly
interconnected pathways and thus they could be better
modulated using small molecules that bind to multiple
disease-relevant proteins.6,7
In this respect, there is a growing interest in designing
molecules with customized polypharmacological profiles by
computational means.8 In particular, current trends point
toward the identification of dual ligands, also referred to as
bispecific small molecules, that specifically bind to two
different target proteins. Among the several publications
describing the design of a bispecific small molecule, the recent
attempts to design a cytotoxic agent that also inhibits P-
glycoprotein for cancer treatment,9 a dual inhibitor of H1 and
H4 that is a more effective antihistamine,10 a dual constitutive
androstane receptor and pregnane X receptor inhibitor for
studying the complex regulation of drug-metabolizing
enzymes,11 and a dual AT1R antagonist and PPARγ partial
agonist for the treatment of hypertension and type 2 diabetes
illustrate both the diversity of therapeutic areas that could be
better addressed with dual inhibitors and the increasing
interest in bispecific small molecule design.
Poly(ADP-ribose) polymerase (PARP) inhibitors are a new
class of therapeutics that block the DNA-repair activity of
several members of the PARP enzyme family.12,13 PARP
inhibitors are designed to compete with the substrate NAD+
and most are inspired on the early chemical tool 3-
aminobenzamide (3-AB; 1), sharing a benzamide pharmaco-
phore (2) that forms a hydrogen-bonding network in the
binding site of PARPs (Figure 1).14 Olaparib was the first
PARP inhibitor to receive FDA approval in 2014 for BRCA-
mutated ovarian cancer and, more recently, rucaparib and
niraparib have been also approved for this indication.12 After
these approvals, the identification of new cancer subtypes and
biomarkers that could enable an extended use of PARP
inhibitors remains a highly active field of study.12 With the
increase in the understanding of the role of PARPs in the
regulation of multiple other physiological and pathophysio-
logical functions, including gene transcription, cell cycle
progression, and cell death, the potential therapeutic use of
PARP inhibitors beyond cancer has also been investigated.15,16
For example, it is now widely documented that extensive
oxidative or nitrosative stress leads to excessive activation of
PARPs, depletion of cellular stores of PARP’s substrate NAD,
and finally to cell death by necrosis.15 Accordingly, PARP
inhibitors could find applications in therapeutic areas that may
benefit from preventing cell death such as cardiovascular or
neurodegenerative diseases. However, the full exploitation of
PARP inhibitors in the clinic is currently hampered by our yet
incomplete understanding of both the biological functions of
PARPs and the (poly)pharmacology of PARP inhibitors.12,13
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Recently, the identification of differential kinase off-targets
among PARP inhibitors has contributed to explain some of the
observed differential cellular effects and facilitate their full
exploitation for patient benefit.13,17−19
The possibility that PARP inhibitors also bind to kinase off-
targets opens an avenue for the generation of dual PARP−
kinasae inhibitors with potential applications in various
therapeutic areas. In this respect, ROCK1 and ROCK2 are
two highly homologous isoforms of Rho-associated protein
kinase (ROCK), responsible for translating the signal from
Rho GTPases into a wide diversity of functions, including cell
motility, cell proliferation, and apoptosis.20,21 Accordingly,
ROCK inhibitors have been extensively investigated in both
cardiovascular diseases and cancer, among other therapeutic
areas.21 In 1995, fasudil (3) was the first ROCK inhibitor to be
approved in Japan to treat cerebral vasospasm (Figure 1).20 In
Figure 1. Chemical structures of PARP and Rho-associated protein kinase (ROCK) inhibitors. (1) 3-aminobenzamide (3-AB). (2) PARP
pharmacophore. (3) Fasudil (ROCK drug). (4) Hydroxyfasudil (metabolite of fasudil). (5) CHEMBL1767049 (PARP inhibitor). (6) UPF 1069
(PARP chemical tool).27
Table 1. Complete Matrix of Affinity Values for Hydroxyfasudil and UPF 1069 against 1, 2, ROCK1, and ROCK2a
compound PARP1 PARP2 ROCK1 ROCK2
hydroxyfasudil 27 ± 1%@10 μM IC50 = 35.1 μM IC50 = 0.8 μM
32 IC50 = 0.6 μM
32
UPF 1069 IC50 = 0.1 μM
29 IC50 = 1 μM
29 IC50 = 9.3 μM 20.5 ± 0.4%@10 μM
aIC50 values (μM) were either generated from this work or directly extracted from the literature (in which case the corresponding literature citation
is included). Percentage of inhibition values at 10 μM came from this work.
Figure 2. Dose−response curves and IC50 calculation of hydroxyfasudil on PARP2 (left) and UPF 1069 on ROCK1 (right) confirm that both small
molecules are dual PARP−ROCK inhibitors.
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humans, fasudil is rapidly transformed to an active metabolite,
hydroxyfasudil (4, Figure 1), that reaches similar concen-
trations but higher half-life time in plasma and thus plays an
important role in fasudil’s therapeutic action.22 A close look at
the chemical structure of hydroxyfasudil reveals that it contains
the benzamide pharmacophore of PARP inhibitors (Figure 1)
and thus it could potentially bind to PARPs as well.
Whereas the off-target kinase polypharmacology of PARP
inhibitors has been identified,13,17 the potential off-target
PARP polypharmacology of kinase inhibitors remains unex-
plored. Most interestingly, it has recently been reported that
the Rho-kinase signaling pathway promotes the expression of
PARP to accelerate cardiomyocyte apoptosis in ischemia and
PARPs and ROCKs also participate in the same pathway to
regulate axon growth.23,24 Therefore, dual PARP−ROCK
inhibitors would be invaluable pharmacological tools to study
the many pathways in which both PARPs and ROCKs
participate and could be used as pathfinder molecules in the
development of more efficacious and robust therapeutics to
modulate these pathways. These observations prompted us to
investigate further the potential cross-pharmacology between
PARP and ROCK inhibitors.
■ RESULTS
Following on the previous observation, hydroxyfasudil was
processed in silico using Chemotargets CLARITY,25 a widely
used and validated predictive pharmacology platform.5,26 Apart
from recovering many of the known interactions with members
of the kinase family, the results predicted a potential affinity for
the protein PARP2 based on the similarity with the
micromolar PARP inhibitor CHEMBL1767049 (5, Figure
1).27 An in vitro biochemical test was subsequently performed
to confirm that indeed hydroxyfasudil inhibits PARP2 in a
dose−response manner. Initially, hydroxyfasufil showed 27% of
PARP1 and 40% of PARP2 inhibition at 10 μM concentration
(Table 1). The dose−response curve of the stronger
interaction between hydroxyfasudil and PARP2 was sub-
sequently calculated, yielding a final IC50 of 35.1 μM (Table 1
and Figure 2). This is an illustrative example of how in silico
pharmacology can be used to anticipate potential off-target
affinities of an active drug metabolite.
On the basis of the previous results,13,17 we were also
intrigued by the possibility that PARP inhibitors could have
some residual ROCK inhibition. Unfortunately, the most
similar PARP inhibitor to hydroxyfasudil, CHEMBL1767049
(Figure 1), was not commercially available.27 However, among
the known PARP chemical tools that present a 2H-isoquinolin-
1-one scaffold substituted at position 7, we found the
commercially available chemical probe UPF 1069 (6, Figure
1).28 UPF 1069 has IC50 values of 0.1 and 1.0 μM for PARP1
and PARP2, respectively (Table 1).29 Accordingly, we tested
this compound using an in vitro biochemical assay against
ROCK1 and ROCK2 and confirmed that UPF 1069 shows
also 38% ROCK1 and 20.5% ROCK2 inhibition at 10 μM
(Table 1). We subsequently calculated the dose−response
curve for the stronger UPF 1069−ROCK1 interaction, which
yielded an IC50 of 9.3 μM (Table 1 and Figure 2).
The identification of two small molecules with low-
micromolar affinities for PARPs and ROCKs is an important
finding that confirms the existence of a certain level of cross-
pharmacology between the members of these two protein
families. However, a key question at this stage is whether those
affinities could actually have some therapeutic relevance. In
this respect, it is known that, in humans, fasudil is rapidly
metabolized to hydroxyfasudil, reaching similar peak plasma
concentrations and with a higher half-life time than
fasudil.22,30,31 Specifically, hydroxyfasudil reaches peak plasma
concentrations of around 0.84−0.56 μM for continuous
infusion of 30−60 mg/min in 30−60 min.22,30,31 Hydrox-
yfasudil has IC50 values of 0.76 and 0.58 μM for ROCK1 and
ROCK2, respectively (Table 1).32 In contrast, the IC50 values
for PARPs are well below their peak plasma concentration
(Table 1 and Figure 2). Therefore, PARP2 is unlikely to be
involved in the mechanism of action of fasudil at these clinical
concentrations. However, even though the dose of 30 mg is the
more commonly used in clinical trials, fasudil has also been
investigated at 80 mg three times daily in a phase 2 clinical trial
of stable angina.33 Following the result that a dose of 80 mg
was found to be safe, this phase 2 trial recommended to
explore higher fasudil doses. Accordingly, it may be important
to bear in mind in the future that the low-micromolar PARP2
affinity of hydroxyfasudil could become therapeutically relevant
at higher clinical doses.33 In fact, it was recently demonstrated
that it is possible to redirect metabolism to increase the
concentration of desired drug metabolites in humans.34
■ DISCUSSION
UPF 1069 and hydroxyfasudil could be invaluable pharmaco-
logical tools to explore the biological relevance of simultaneous
PARP−ROCK inhibition. To gain a deeper insight into its
potential therapeutic relevance, we used the Open Targets
resource35 to prioritize disease areas where both targets are
involved. Open Targets is a platform that links targets with
diseases using public and newly generated data, including text
mining, genomics, and transcriptomics, among others. Using
PARP1 and ROCK1 as queries, we identified seven therapeutic
areas with more than 15 diseases each that are shared between
PARP and ROCK, illustrating the involvement of both targets
in similar diseases and processes (Figure 3). Not surprisingly,
Figure 3. Venn diagram of shared therapeutic areas between PARP1
and ROCK1 extracted from the Open Targets platform.44 Font size is
proportional to the number of shared diseases inside each therapeutic
area (see Materials and Methods).
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cancer (under the Open Targets therapeutic areas of
“neoplasms” and “genetic diseases”) emerged as the
therapeutic area with the highest number of shared diseases,
given the approval of PARP inhibitors in ovarian cancer and its
investigation in several other types of cancer and the vast
literature linking ROCKs to cancer.20,21 Interestingly, simulta-
neous inhibition of ROCKs could be beneficial in most of the
cancer types where PARP inhibitors are being investigated in
last-stage clinical trials, such as prostate and breast cancer,
mainly due to the involvement of ROCKs in extracellular
matrix remodeling and metastasis.21
Dual PARP−ROCK inhibition could also be beneficial in
several eye diseases, including diabetic retinophaty, a serious
chronic microvascular complication of diabetes mellitus and a
leading cause of blindness in industrialized regions.36,37
ROCK1 kinase upregulation has been implicated in the
microvascular endothelial cell dysfunction associated with
diabetic retinophaty, whereas a PARP1 knockout in mice has
demonstrated the role of PARP1 in the inflammatory response
that drives this disease; thus, simultaneous inhibition of PARPs
and ROCKs could be beneficial to treat diabetic retino-
phaty.36,37
Nervous system diseases also emerge as complex diseases
that could benefit from dual inhibition of PARPs and ROCKs.
From this analysis, Alzheimer’s disease (AD) emerges as a
potential candidate for a dual inhibitor of ROCKs and PARPs.
On the one side, the peptide β-amyloid (Aβ), which is itself an
AD hallmark and toxic, has been shown to also activate
PARP1, leading to neuronal cell death.38 On the other side,
ROCK1 has also been suggested as a potential therapeutic
target in AD, given its role in regulating Aβ production,
secretion, and post-translational modification.39 Given the high
unmet need that AD represents and the clinical failures due to
the lack of efficacy of all AD therapies investigated so far, dual
inhibitors of PARPs and ROCKs could facilitate the
simultaneous study of these two therapeutic strategies in an
attempt to increase success rates. In addition, it has been
recently shown that PARP1 acts in the RhoA/ROCK pathway
that inhibits axon growth and thus the dual inhibition of
PARPs and ROCKs could also facilitate axon regrowth after
acute axonal injury.24
Several cardiovascular diseases are also modulated by both
ROCKs and PARPs, including ischemia−reperfusion injury.
PARP1 hyperactivation has long been implicated in cell death
after ischemia−reperfusion injury due to the depletion of
NAD+.40 Moreover, ROCKs have been shown to reduce
myocardial infarction size and prevent cardiomyocyte
apoptosis.23 Even more interestingly, a very recent study
suggests that ROCKs regulate PARP1 expression and
participate in the same pathway to accelerate cardiomyocyte
apoptosis, suggesting potential synergistic effects of dual
PARP−ROCK inhibitors on blocking cell death after
ischemia−reperfusion.23 To complete the list of therapeutic
areas that are shared between PARPs and ROCKs, several skin
and skeletal system diseases could also benefit from
simultaneous modulation of PARPs and ROCKs, thus
highlighting the wide diversity of opportunities that dual
PARP−ROCK chemical tools could unlock toward designing
more effective therapeutics.
■ CONCLUSIONS
We have identified hydroxyfasudil and UPF 1069 as interesting
complementary chemical seeds from which small-molecule
tools with optimized dual PARP−ROCK inhibition could be
generated. When administered at high concentrations, they
could already be used to study the biological relevance of dual
PARP−ROCK inhibition, which could potentially be exploited
in a large number of complex therapeutic areas where both
targets are involved. We hope that these findings contribute to
increase our understanding of PARP−kinase cross-pharmacol-
ogy and unlock the design of more efficacious therapeutics that
are capable of modulating robust pathways altered in diseases
of high unmet medical need.
■ MATERIALS AND METHODS
Chemicals and Reagents. Hydroxyfasudil hydrochloride
(Catalog No. 14413) was obtained from Cayman Chemical
(Ann Arbor, MI), and UPF 1069 (Catalog No. S8038) was
purchased from SelleckChem (Houston, TX), both with
guaranteed purity of >98%.
In Silico Target Profiling. Chemical structures were
processed with Chemotargets CLARITY v1.0.4.25 Given the
two-dimensional structure of a molecule (smiles or sd/mol
file), CLARITY returns the predicted affinities for those targets
for which ligand information is available in selected public and
patent sources of pharmacological data. Six ligand-based
approaches are implemented in CLARITY v1.0.4 that rely on
molecular similarity, an implementation of the similarity
ensemble approach, fuzzy fragment-based mapping, quantita-
tive structure−activity relationships, machine learning methods
(including support vector machine, random forest, and neural
networks), and target cross-pharmacology.41 The method has
been successfully and extensively used and validated both
retrospectively and prospectively.5,26,41
In Vitro Biochemical Assays of ROCK1 and ROCK2
Activities. The effects of compounds on the activity of the
human ROCK1 and ROCK2 were quantified by measuring the
phosphorylation of the substrate Ulight-RRRSLLE (PLK)
using a human recombinant enzyme and the LANCE detection
method. Both assays were performed at the contract research
organization company Eurofins Pharma Discovery Services.42
The test compound, reference compound, or water
(control) were mixed with the enzyme (8.2 ng of ROCK1;
4.52 ng of ROCK2) in a buffer containing 40 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid/Tris (pH 7.4),
0.8 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-
tetraacetic acid/Tris, 8 mM MgCl2, 1.6 mM dithiothreitol, and
0.008% Tween 20. Thereafter, the reaction was initiated by
adding the substrate Ulight-RRRSLLE (50 nM for ROCK1;
100 nM for ROCK2) and ATP (1 μM for ROCK1; 10 μM for
ROCK2), and the mixture was incubated (20 min for ROCK1;
15 min for ROCK2) at room temperature. For control basal
measurements, the enzyme was omitted from the reaction
mixture. Following incubation, the reaction was stopped by
adding 13 mM ethylenediaminetetraacetic acid. After 5 min,
the anti-phospho-PLK antibody labeled with europium chelate
was added. After 60 more min, the fluorescence transfer was
measured at λex = 337 nm, λem = 620 nm, and λem = 665 nm
using a microplate reader (Envision, PerkinElmer). The
enzyme activity was determined by dividing the signal
measured at 665 nm by that measured at 620 nm (ratio).
The results were expressed as a percent inhibition of the
control enzyme activity. The standard inhibitory reference
compound used was staurosporine, which was tested in each
experiment at several concentrations to obtain an inhibition
curve from which its IC50 value was calculated.
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In Vitro Biochemical Assays of PARP1 and PARP2
Activities. Both assays were performed by following the BPS
PARP assay kit protocols.43 The enzymatic reactions were
conducted at room temperature for 1 h in a 96-well plate
coated with the histone substrate. The reaction buffer (50 μL)
(Tris−HCl, pH 8.0) contains 2.5 μM NAD+, 2.5 μM
biotinylated NAD+, 0.026 mg/mL activated DNA, the
corresponding human PARP enzyme (10 ng of PARP1,
catalog number 80501 (Lot number 160524B); 25 ng of
PARP2, catalog number 80502 (Lot number 140729-P4)), and
the test compound at the corresponding concentration
(hydroxyfasudil hydrochloride hydrate). After enzymatic
reactions, 50 μL of streptavidin−horseradish peroxidase was
added to each well, and the plate was incubated at room
temperature for an additional 30 min. Developer reagents (100
μL) were added to wells, and luminescence was measured
using a BioTek Synergy 2 microplate reader.
The luminescence data were analyzed using computer
software Graphpad Prism. In the absence of the compound,
the luminescence (Lt) in each data set was defined as 100%
activity. In the absence of the PARP, the luminescence (Lb) in
each data set was defined as 0% activity. The percent activity in
the presence of each compound was calculated according to
the following equation: % activity = [(L − Lb)/(Lt − Lb)] ×
100, where L is the luminescence in the presence of the
compound, Lb is the luminescence in the absence of the PARP,
and Lt is the luminescence in the absence of the compound.
The percent inhibition was calculated according to the
following equation: % inhibition = 100 − % activity.
Analysis of Therapeutic Areas Using the Open Target
Platform. PARP1 and ROCK1 were used as queries in the
Open Targets platform website.44 Next, the number of diseases
for each therapeutic area was obtained from the resource. Only
therapeutic areas with more than 15 positively associated
diseases with both PARP1 and ROCK1 were considered
further. Finally, the evidence provided in the Open Targets
platform was further investigated, focusing on the literature
references that were carefully read to identify the diseases
where simultaneous inhibition of PARP1 and ROCK1 could
be beneficial.
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